Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR ... GlobeNewswire (press release) SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, ... Celladon Gets FDA's “Breakthrough Therapy” Status for Gene Therapy Celladon Gets Breakthrough Therapy Designation For Mydicar From FDA |
